Get the Stockscreener App
4.36
0.68%
-0.03
Cingulate Inc stock is traded at $4.36, with a volume of 228.56K.
It is down -0.68% in the last 24 hours and down -14.34% over the past month.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.
See More
Previous Close:
$4.39
Open:
$4.39
24h Volume:
228.56K
Relative Volume:
2.11
Market Cap:
$63.40M
Revenue:
Net Income/Loss:
$-27.71M
P/E Ratio:
-1.0231
EPS:
-4.2615
Net Cash Flow:
$-19.77M
1W Performance:
-10.84%
1M Performance:
-14.34%
6M Performance:
-17.11%
1Y Performance:
+14.74%
1-Day Range:
$4.12
$4.44
1-Week Range:
$4.12
$4.94
52-Week Range:
$3.16
$11.89
Cingulate Inc Stock (CING) Company Profile
Name
Cingulate Inc
Sector
Industry
Phone
(913) 942-2300
Address
1901 W. 47TH PLACE, KANSAS CITY
Compare CING vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CING
Cingulate Inc
|
4.36 | 63.40M | 0 | -27.71M | -19.77M | -4.2615 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cingulate Inc Stock (CING) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-10-25 | Initiated | ROTH MKM | Buy |
| Dec-22-23 | Downgrade | Laidlaw | Buy → Hold |
Cingulate Inc Stock (CING) Latest News
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance Australia
Cingulate Warrants (CINGW) Hold Flat at $0.01 as Micro-Cap Warrant Sits at Its Pricing FloorEqual Weight ETF - siam.in
Cingulate Warrants (CINGW) Hold Flat at $0.01 as Micro-Cap Warrant Sits at Its Pricing FloorLeveraged ETF Flow - www.dars.gov.et
Cingulate Inc. (CING) Q2 2026 Earnings: Narrower-Than-Expected Loss Offers Modest Relief, but No Revenue Yet - dars.gov.et
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceEase of Movement - careplusvn.com
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceWave Truncation - siam.in
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceLeveraged ETF Flow - dars.gov.et
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceElliott Wave Entry - https://www.dars.gov.et/
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceTurnaround Stocks - dars.gov.et
CING Q2 2026 Earnings: Narrower Loss Delivers 29.4% EPS SurpriseRevenue Report - vinanet.vn
Caring Brands Inc. (Nasdaq: CABR) Completes Initial $4.6 Million Closing Under Ongoing $9 Million Private Placement - Yahoo Finance
Cingulate Inc. Warrants (CINGW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Cingulate Inc. Warrants (CINGW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) - theglobeandmail.com
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionBasic EPS Analysis - vinanet.vn
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionFinancial Data - dars.gov.et
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionDividend Cut Risk - dars.gov.et
Zacks Research Has Bullish Outlook for Cingulate Q3 Earnings - MarketBeat
Ascendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00 - MarketBeat
CINGULATE INC : ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $44 FROM $52 - Bitget
Cingulate (CING) Results at a Glance: The EPS Result Is Below Expectation in Latest Trading; Market Reaction: The Market Price Moves 1.35% Higher in the Current UpdateCFO Commentary Report - dars.gov.et
Cingulate (CINGW) Levels: Finishes 26.88% Up at $0.01 at the Close; Trading Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseValue Area Low - vinanet.vn
Cingulate (CING) Quarterly Results: EPS Comes in Below Forecast; Closing Move: Shares Close 1.73% Higher in Latest TradingSurprise Factor Analysis - vinanet.vn
CING: Second Quarter Results - Yahoo Finance
Cingulate (CING) Results Breakdown: EPS Comes in Below Forecast at the Close; Market Read: The Share Price Sheds 0.19% in the Latest SessionEarnings Revision Upgrade - vinanet.vn
Cingulate CEO Dr. Shane J. Schaffer: Why a Child's ADHD Diagnosis Often Reveals ADHD in a Parent - inkl
Cingulate CEO Dr. Shane J. Schaffer: Why a Child's ADHD Diagnosis Often Reveals ADHD in a Parent - International Business Times
CING Q1 2026 Earnings: Wider-Than-Expected Loss of -$0.95 Per Share as Clinical-Stage Costs Persist - vinanet.vn
Cingulate (NASDAQ:CING) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Cingulate Stock Price Forecast. Should You Buy CING? - StockInvest.us
Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results - MarketBeat
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com Australia
Form 8K Cingulate Inc For: 13 August - Investing.com Nigeria
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com Canada
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug - Investing.com Nigeria
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com Canada
Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary - TradingView
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com Australia
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com India
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug - Investing.com
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com South Africa
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com UK
Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash - Quiver Quantitative
Cingulate Reports Q2 2026 Results: $28.4M Cash; Net Loss $5.9M for Quarter - TradingView
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com India
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com UK
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness - marketscreener.com
Cingulate Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Pagaya Technologies Warrants (PGYWW) Drop 7.02% to $0.03 as Trading Remains Pinned at Penny LevelETH Profile - careplusvn.com
Cingulate Inc. Warrants (CINGW) Rise 9.72% to $0.01 as Support and Resistance AlignTrend Following Picks - vinanet.vn
Cingulate Inc Stock (CING) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cingulate Inc Stock (CING) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Werth Peter J. | Director |
Feb 06 '26 |
Buy |
5.04 |
19,455 |
98,053 |
117,449 |
| Callahan Jennifer L. | SVP and CFO |
Feb 06 '26 |
Buy |
5.04 |
4,864 |
24,515 |
5,059 |
| Schaffer Shane J. | Chief Executive Officer |
Feb 06 '26 |
Buy |
5.04 |
6,809 |
34,317 |
10,175 |
| Brams Matthew | EVP and Chief Medical Officer |
Feb 06 '26 |
Buy |
5.04 |
1,946 |
9,808 |
4,656 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):